Anti-hCD19-CD3

Bispecific antibody against human CD19 and human CD3

Catalog code: bimab-hcd19cd3

https://www.invivogen.com/anti-hcd19-cd3

For research use only, not for diagnostic or therapeutic use

Version 18I11-NJ

PRODUCT INFORMATION

Contents: 10 µg Anti-hCD19-CD3, purified antibody, provided azide-free and lyophilized
Target: Human CD19 (hCD19) and human CD3 (hCD3)
Specificity: Cells expressing hCD19 and hCD3
Clonality: Monoclonal antibody
Source: CHO (Chinese hamster ovary) cells
Formulation: Anti-hCD19-CD3 is lyophilized from a 0.2 µm filtered phosphate buffer solution (pH 7.4) containing 5% saccharose.
Purity: > 90%. Purified by affinity chromatography

Antibody resuspension

Add 100 µl of sterile water to obtain a concentration of 0.1 mg/ml. Invert vial several times to ensure the product is fully dissolved.

Storage and stability

- Product is shipped at room temperature. Store lyophilized antibody at -20 °C. Lyophilized product is stable for at least 1 year.
- Reconstituted antibody is stable for 1 month when stored at 4 °C and for 1 year when aliquoted and stored at -20 °C. Avoid repeated freeze-thaw cycles.

Quality control

- Binding to hCD19 and to hCD3 has been confirmed by flow cytometry.
- Biological activity has been confirmed using cellular assays.
- The complete sequence of this antibody has been verified.
- The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.

DESCRIPTION

Anti-hCD19-CD3 is a bispecific antibody that binds to two sites: hCD19 expressed on the surface of B cells, and hCD3, part of the T cell receptor. It features Blinatumomab single-chain variable fragments (scFv) joined by a glycine-serine linker. These two scFvs have been cloned from the anti-hCD19 (clone HD37) and anti-hCD3 (clone L2K-07) monoclonal antibodies[1,2]. Blinatumomab is a bispecific antibody used for the treatment of refractory acute lymphocytic leukemia (ALL). By binding to hCD3 and hCD19, Blinatumomab engages unstimulated T cells to proliferate and exert cytotoxic activity on CD19-positive lymphoma cells[2] (Figure 1). Of note, Blinatumomab does not cross-react with CD3 and CD19 from mice, rats, or dogs[3].

1. Krishnamurthy A. & Jimeno A., 2017. Bispecific antibodies for cancer therapy: A review. Pharmacol Ther. S0163-7258(17)30293-0**. 2. Bargou R. *et al.*, 2008.** Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody. Science. 321(5891):974-7. **3. Trivedi A. *et al.*, 2017.** Clinical Pharmacology and Translational Aspects of Bispecific Antibodies. Clin Transl Sci. 10(3):147-162.



Figure 1: Anti-hCD19-CD3 binds to hCD3 on T cells and to hCD19 on B cells leading to T cell proliferation and B cell lysis.

APPLICATION

Anti-hCD19-CD3 bispecific antibody can be used for fine-tuning studies of B cell contact-dependent killing and T cell activation/proliferation.

PROCEDURE

InvivoGen has developed a cellular assay to determine the ability of Anti-hCD19-CD3 to activate T cells in the presence of CD19-positive B cells. This assay utilizes the human B-cell lymphoma cell line Raji and InvivoGen's Jurkat-Lucia™ NFAT cells, an immortalized T lymphocyte cell line that stably expresses an NFAT-inducible Lucia luciferase reporter gene (Figure 2, next page).

For more information visit http://www.invivogen.com/jurkat-lucia-nfat-cells.

Determination of T cell activation using Jurkat-Lucia™ NFAT cells

1. Dispense 20 µl of Anti-hCD19-CD3 (0.1-100 ng/ml final concentration) diluted in IMDM (Isocove's Modified Dulbecco's Medium) containing 10% heat-inactivated fetal bovine serum per well of a 96-well plate.
Note: We recommend using Anti-βGal-hCD3 and Anti-hCD19-βGal as negative controls.
2. Into each well, distribute 90 µl of Raji cell suspension (100,000 cells/well).
3. Incubate 30 minutes at 37°C.
4. Into each well, distribute 90 µl of Jurkat-Lucia™ NFAT cell suspension (300,000 cells/well).
5. Incubate for 6, 8 and 24 hours at 37°C.
6. Levels of Lucia luciferase can be determined by measuring the luminescence at each time point using coelenterazine-based reagents such as QUANTI-Luc™ and QUANTI-Luc™ Gold.

TECHNICAL SUPPORT
InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Hong Kong: +852 3622-3480
E-mail: info@invivogen.com



Figure 2: Jurkat-Lucia™ NFAT cell activation upon incubation with Raji B cells and Anti-hCD19-CD3.

Note: *Jurkat T cells are $CD4^+CD8^-$. To assess B-cell lysis, we recommend to use primary $CD8^+$ T cells.*

RESTRICTION USE

This antibody is distributed for research purposes only. It is not intended for diagnosis or therapeutic use.

RELATED PRODUCTS

Product	Catalog Code
Anti-βGal-hCD3 (negative control)	bimab-bgalhcd3
Anti-hCD19-βGal (negative control)	bimab-hcd19bgal
Jurkat-Lucia™ NFAT Cells	jktl-nfat
QUANTI-Luc™	rep-qlc1
QUANTI-Luc™ Gold	rep-qlcg1